[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stem-cell-transplant-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stem-cell-transplant-complications":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,45,94,129,157,182,204,225,252,276,298,324,351,373,398,419,440,459,485,517,541,568,590],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100636232","phase-2-menin-inhibitor-targeted-maintenance-in-aml-100636232",false,"NCT07563010","Menin-Inhibitor Targeted Maintenance in AML","Phase 2 Randomized Controlled Study of Revumenib as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With KMT2Ar, NPM1m, or NUP98r Acute Myeloid Leukemia (AML)","Inclusion Criteria:\n\nInclusion Criteria:\n\n1. Aged ≥18 years at the time of signing informed consent\n2. Able to provide written informed consent personally or via a legally authorized representative in accordance with applicable regulatory and institutional requirements\n3. Willing and able to comply with all study procedures and available for the duration of the study\n4. Diagnosis of acute myeloid leukemia (AML) in complete morphologic remission with one of the following molecular abnormalities:\n\n1\\. KMT2A-rearranged (KMT2Ar) AML (Excluding KMT2A partial tandem duplication (KMT2A-PTD) 2. NPM1-mutated (NPM1m) AML (Including FLT3-ITD or TKD co-mutation) 3. NUP98-rearranged (NUP98r) AML 5. Planned first allogeneic hematopoietic cell transplantation (allo-HCT) for AML.\n\n6\\. Transplant Characteristics\n\n1. Planned allo-HCT using bone marrow or peripheral blood stem cell graft source.\n2. Planned reduced-intensity\u002Fnon-myeloablative conditioning (RIC\u002FNMA) or myeloablative conditioning (MAC), using a conditioning regimen permitted- by the protocol and consistent with standard clinical practice, meeting CIBMTR criteria for conditioning intensity\n\n7\\. Planned donor:\n\n1. HLA-matched related donor (5\u002F6 or 6\u002F6)\n2. Matched unrelated donor (8\u002F8)\n3. Mismatched unrelated donor (7\u002F8)\n4. Haploidentical donor meeting institutional requirements\n\n8\\. Performance Status:\n\n1\\. Karnofsky Performance Status ≥70%. 9. Cardiac Function: left ventricular ejection fraction (LVEF) by transthoracic echocardiogram (TTE) or multigated acquisition (MUGA) with no clinical evidence of heart failure: RIC\u002FNMA: ≥50% MAC: ≥5 10. Pulmonary function meeting the following criteria, without supplemental oxygen other than CPAP:\n\n1. RIC\u002FNMA: DLCO (corrected for hemoglobin) and FEV1 ≥40% predicted\n2. MAC: DLCO and FEV1 ≥50% predicted\n\n11\\. Renal Function: estimated creatinine clearance (CrCl) ≥45mL\u002Fmin calculated using the Cockcroft-Gault formula or 24-hour urine collection, consistent with standard eligibility criteria for allogeneic HCT recipients.\n\n12\\. Liver function acceptable per local institutional guidelines for allo-HCT eligibility.\n\n13\\. Reproductive Status: Willingness to use contraception in accordance with local regulations from first study intervention through the required contraceptive period Willingness to use contraception in accordance with local regulations from first study intervention through the required contraceptive period\n\nExclusion Criteria:\n\n1. Disease Status:\n\n   a. Evidence of active AML prior to HCT, assessed within 42 days before transplant, defined as any of the following:\n   * ≥5% bone marrow blasts\n   * Circulating blasts within 14 days before conditioning\n   * CNS or other extramedullary disease\n2. Other active malignancy that, in the investigator's judgment, could interfere with safety or efficacy assessment\n3. Treatment with non-protocol antileukemic therapy (donor lymphocyte infusion for relapse prophylaxis or treatment will be considered an EFS event)\n4. Cardiac \u002F QT Risk\n\n   1. Requirement for concomitant medications known to prolong QT\u002FQTc interval, except low-risk agents used as standard supportive care\n   2. Diagnosis or suspicion of Long QT syndrome, or a family history of Long QT syndrome\n   3. Fridericia's corrected QT interval (QTcF) \\>450 msec.\n   4. History within 6 months of study entry of:\n\n   i. Myocardial infarction ii. Unstable angina iii. Congestive heart failure (NYHA Class ≥ II) iv. Life-threatening or uncontrolled arrhythmia v. Cerebrovascular accident or transient ischemic attack\n5. Chronic respiratory disease requiring continuous supplemental oxygen, or other significant organ dysfunction that would adversely affect study participation.\n6. Active, uncontrolled infection, including any of the following:\n\n   1. Active, uncontrolled systemic fungal, bacterial, or viral infection within 14 days prior to the start of conditioning\n   2. Any other documented active, uncontrolled infection at the start of conditioning\n7. Chronic viral infections with evidence of active disease, including:\n\n   HIV: detectable viral load within 6 months prior to screening\n\n   Hepatitis B:\n   * HBsAg-positive and\u002For anti-HBc-positive with detectable HBV DNA\n   * Anti-HBc-positive alone Hepatitis C: positive HCV antibody with detectable HCV RNA\n8. Planned HCT using cord blood, ex vivo T cell depletion, engineered grafts, or experimental graft sources\n9. Malabsorption syndrome or GI condition that precludes oral administration, including:\n\n   1. Inability to swallow oral medications\n   2. Prior gastric bypass or severe gastroparesis\n   3. Cirrhosis with Child-Pugh Class B or C\n10. Pregnant or breastfeeding\n11. Prior intolerance to menin inhibitor therapy resulting in ≥ Grade 3 treatment-related adverse events\n12. Any condition, therapy, laboratory abnormality, or allergy to excipients that, in the investigator's judgment, could confound study results, interfere with the participant's ability to comply with study procedures or complete the study, or make participation not in the participant's best interest.","ALL","18 Years",{"count":19,"type":20},146,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML. In addition to suppressing leukemogenic transcriptional programs and promoting leukemic differentiation, menin inhibition has been shown to modulate epigenetic states linked to antigen presentation and immune recognition. These properties provide a strong biological rationale for evaluating revumenib as maintenance therapy following alloHCT, with the goal of suppressing residual leukemic clones while preserving or enhancing GVL activity during immune reconstitution.",[26,27,28,29],"Relapsed Adult AML","Stem Cell Transplant Complications","Acute Myeloid Leukemia","Transplant-Related Hematologic Malignancy",[31,32],"Allogenic Transplant","post-transplant relapse prevention","NOT_YET_RECRUITING","2026-06-16",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":20},"2026-12",{"date":41,"type":20},"2031-06",{"name":43,"class":44},"Center for International Blood and Marrow Transplant Research","NETWORK",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":93},"100316038","phase-3-a-phase-3-study-of-tabelecleucel-for-participants-with-epstein-barr-virus-associated-post-transplant-lymphoproliferative-disease-after-failure-with-rituximab-or-rituximab-and-chemotherapy-100316038","NCT03394365","A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy","Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy","ALLELE","Inclusion Criteria:\n\n1. Prior SOT of kidney, liver, heart, lung, pancreas, small bowel, or any combination of these (C-SOT); or prior allogeneic HCT (C-HCT).\n2. A diagnosis of locally assessed, biopsy-proven EBV+ PTLD.\n3. Availability of appropriate partially HLA-matched and restricted tabelecleucel has been confirmed by the sponsor.\n4. Measurable, 18F-deoxyglucose (FDG)-avid (Deauville score ≥ 3) systemic disease using Lugano Classification response criteria by positron emission tomography (PET)-diagnostic computed tomography (CT), except when contraindicated or mandated by local practice, then magnetic resonance imaging (MRI) may be used. For participants with treated central nervous system (CNS) disease, a head CT and\u002For brain\u002Fspinal MRI as clinically appropriate will be required to follow CNS disease response per Lugano Classification response criteria.\n5. Treatment failure of rituximab or interchangeable commercially available biosimilar monotherapy (C-SOT-R or C-HCT) or rituximab plus any concurrent or sequentially administered chemotherapy regimen (C-SOT-R+C) for treatment of PTLD.\n6. Males and females of any age.\n7. Eastern Cooperative Oncology Group performance status ≤ 3 for participants aged ≥ 16 years; Lansky score ≥ 20 for participants \\\u003C 16 years.\n8. For C-HCT only: If allogeneic HCT was performed as treatment for an acute lymphoid or myeloid malignancy, the underlying primary disease for which the participant underwent transplant must be in morphologic remission.\n9. Adequate organ function.\n\n   1. Absolute neutrophil count ≥ 1000\u002FμL, (C-SOT) or ≥ 500\u002FμL (C-HCT), with or without cytokine support.\n   2. Platelet count ≥ 50,000\u002FμL, with or without transfusion or cytokine support. For C-HCT, platelet count \\\u003C 50,000\u002FμL but ≥ 20,000\u002FμL, with or without transfusion support, is permissible if the participant has not had grade ≥ 2 bleeding in the prior 4 weeks (where grading of the bleeding is determined per the National Cancer Institute's Common Terminology Criteria for Adverse Events \\[CTCAE\\], version 5.0).\n   3. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin each \\\u003C 5 × the upper limit of normal; however, ALT, AST, and total bilirubin each ≤ 10 × upper limit of normal is acceptable if the elevation is considered by the investigator to be due to EBV and\u002For PTLD involvement of the liver as long as there is no known evidence of significant liver dysfunction.\n10. Participant or participant's representative is willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Currently active Burkitt, T-cell, NK\u002FT-cell lymphoma\u002FLPD, Hodgkin, plasmablastic, transformed lymphoma, active hemophagocytic lymphohistiocytosis, or other malignancies requiring systemic therapy.\n2. Daily steroids of \\> 0.5 mg\u002Fkg prednisone or glucocorticoid equivalent, ongoing methotrexate, or extracorporeal photopheresis.\n3. Untreated CNS PTLD or CNS PTLD for which the participant is actively receiving CNS-directed chemotherapy (systemic or intrathecal) or radiotherapy at enrollment. NOTE: Participants with previously treated CNS PTLD may enroll if CNS-directed therapy is complete.\n4. Suspected or confirmed grade ≥ 2 graft-versus-host disease (GvHD) per the Center for International Blood and Marrow Transplant Research consensus grading system at enrollment.\n5. Ongoing or recent use of a checkpoint inhibitor agent (eg, ipilimumab, pembrolizumab, nivolumab) within 3 drug half-lives from the most recent dose to enrollment.\n6. For C-HCT: active adenovirus viremia.\n7. Need for vasopressor or ventilatory support.\n8. Antithymocyte globulin or similar anti-T cell antibody therapy ≤ 4 weeks prior to enrollment.\n9. Treatment with Epstein-Barr virus cytotoxic T lymphocytes or chimeric antigen receptor T cells directed against B cells within 8 weeks of enrollment (C-SOT or C-HCT), or unselected donor lymphocyte infusion within 8 weeks of enrollment (C-HCT only).\n10. Female who is breastfeeding or pregnant or female of childbearing potential or male with a female partner of childbearing potential unwilling to use a highly effective method of contraception.\n11. Inability to comply with study-related procedures.\n12. Any medical condition or organ system dysfunction that in the investigator';s opinion, could compromise the participant's safety or ability to complete the study.",{"count":54,"type":20},115,[56],"PHASE3","The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.",[59,60,61,62,27],"Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)","Solid Organ Transplant Complications","Lymphoproliferative Disorders","Allogeneic Hematopoietic Cell Transplant",[64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,62,81],"Epstein-Barr Virus (EBV)-associated Lymphoproliferative Disease (LPD)","Epstein-Barr Virus (EBV)","Cytotoxic T lymphocyte (CTL)","Cancer After Transplant","Kidney transplant","Renal transplant","Liver transplant","Heart transplant","Lung transplant","Intestinal transplant","Pancreas transplant","Post-transplant Lymphoma","Solid Organ Transplant (SOT)","Bone Marrow Transplant Complications","Epstein-Barr Virus-specific Cytotoxic T Lymphocytes (EBV-CTL)","Hematopoietic Cell Transplant (HCT)","Hematopoietic Stem Cell Transplantation (HSCT)","Allogeneic, Off-The-Shelf T-cell Immunotherapy","RECRUITING","2026-05-20",{"date":85,"type":37},"2026-05-22",{"date":87,"type":37},"2017-12-29",{"date":89,"type":20},"2030-08",{"name":91,"class":92},"Pierre Fabre Medicament","INDUSTRY",71,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":128},"100302225","phase-2-nonmyeloablative-stem-cell-transplant-in-children-with-sickle-cell-disease-and-a-major-abo-incompatible-matched-sibling-donor-100302225","NCT03214354","Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor","A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-AID)","Sickle-AID","Inclusion Criteria:\n\n* Patients must be ≥ 12 months and \\\u003C 19 years of age at the time of study enrollment.\n* Patients must have sickle cell disease as defined by hemoglobin electropheresis, as follows:\n\n  * homozygous Hb S disease (HbSS),\n  * sickle-Hb C disease (HbSC),\n  * sickle beta-plus-thalassemia (HbS\u002Fβ+), or\n  * sickle beta-null-thalassemia (HbS\u002Fβo)\n* Patients must meet standard eligibility criteria to undergo HSCT, including but not limited to one or more of the following:\n\n  * history of repeated (more than 1) bony (vaso-occlusive) crisis\n  * history of stroke\n  * elevated transcranial Doppler velocity not eligible for hydroxyurea, as per TWiTCH trial (ie. severe vasculopathy)\n  * history of acute chest crisis or splenic sequestration crisis\n  * history of priapism in males\n  * history of osteonecrosis\n  * pulmonary hypertension as documented by tricuspid regurgitation jet velocity (TRV) \\> 2.5 m\u002Fs on echocardiogram\n  * red cell allo-immunization (≥ 2 antibodies) during long term transfusion therapy\n* Sickle complications should be present despite the use of hydroxyurea, but this is not an absolute requirement, if the treating team considers the patient to be at high risk for further crisis episodes.\n\nExclusion Criteria:\n\n* Patients who are unable to comply with or follow the study protocol.\n* Patients with known hypersensitivity to sirolimus, its derivatives or to any of its components.","1 Year","19 Years",{"count":105,"type":20},12,[23],"The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The nonmyeloablative regimen will use alemtuzumab, total body irradiation (TBI) and sirolimus for immune suppression. This study will expand the access of HSCT for patients with SCD who are currently not eligible because of donor restrictions.",[109,27,110,111],"Sickle Cell Disease","Red Blood Cell Disorder","Pure Red Cell Aplasia",[113,114,115,116,117],"sickle cell disease","stem cell transplant","red blood cell engraftment","nonmyeloablative","pure red cell aplasia","2026-04-27",{"date":120,"type":37},"2026-05-01",{"date":122,"type":37},"2017-07-05",{"date":124,"type":20},"2028-07",{"name":126,"class":127},"University of Calgary","OTHER",1,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":137,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":128},"100632135","phase-2-novel-therapies-for-severe-acute-gvhd-graft-versus-host-disease-100632135","NCT07509749","Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)","Prospective Randomized Controlled Trial of Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)","GVHD","Inclusion Criteria:\n\n1. diagnosed with hematological diseases.\n2. Have undergone first allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies.\n3. New onset of severe acute GVHD within 100 days post-transplantation.\n\nExclusion Criteria:\n\n1. Recipients of second allogeneic stem cell transplant.\n2. Acute GVHD induced by donor lymphocyte infusion, interferon.\n3. Received first line aGVHD treatment before enrollment.\n4. Overlap GVHD syndrome.\n5. Pregnant or breast-feeding women.\n6. Absolute neutrophil count (ANC) \\\u003C0.5×10e9\u002FL or platelet count (PLT) \\\u003C 20×10e9\u002FL.\n7. Serum creatinine \\> 2.0 mg\u002FdL or creatinine clearance \\\u003C 40 mL\u002Fmin measured or calculated by Cockroft-Gault equation.\n8. Uncontrolled infection.\n9. Human immunodeficiency virus infection.\n10. Active hepatitis b virus, hepatitis C virus infection and need antivirus treatment.\n11. Subjects with evidence of relapsed primary disease, or subjects who have been treated for relapse after the allo-HSCT was performed, or graft rejection.\n12. Allergic history to Janus kinase inhibitors.\n13. Severe organ dysfunction unrelated to underlying GVHD, including:\n\n(1)Cholestatic disorders or unresolved veno-occlusive disease of the liver (defined as persistent bilirubin abnormalities not attributable to GVHD and ongoing organ dysfunction).\n\n(2)Clinically significant or uncontrolled cardiac disease including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia that requires therapy.\n\n(3)Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen.\n\n14.Received Janus kinase inhibitor therapy after allo-HSCT for any indication. 15.Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.","14 Years",{"count":139,"type":20},54,[23],"The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for the severe acute GVHD (graft-versus-host disease )",[143,27],"GVHD, Acute",[145,146,147],"acute graft-versus-host disease","Ruxolitinib","first line therapy","2026-03-29",{"date":150,"type":37},"2026-04-03",{"date":152,"type":37},"2025-06-30",{"date":154,"type":20},"2027-12-30",{"name":156,"class":127},"Daihong Liu",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":21,"phases":167,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":181},"100557660","a-novel-digital-application-shift-to-improve-outcomes-for-hematopoietic-stem-cell-transplant-survivors-100557660","NCT06541002","A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors","Multi-Site Randomized Controlled Trial of a Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors","SHIFT","Inclusion Criteria:\n\n* Adult patients (\\> 18 years) who underwent autologous or allogeneic HCT \\> three months prior to study enrollment\n* Screen positive for sexual health concerns causing distress based on the National Comprehensive Network (NCCN) survivorship guidelines screening questions\n\nExclusion Criteria:\n\n* Patients who do not comprehend English or Spanish since SHIFT will only be available in these two languages for this efficacy trial.\n* Patients with any major uncontrolled psychiatric disorder or other comorbid cognitive conditions, which the treating HCT clinician believes would prohibit the patients' capacity to provide informed consent and participate in study procedures.\n* Patients with relapsed disease requiring treatment.",{"count":166,"type":20},300,[168],"NA","This research study is evaluating the efficacy of a novel self-administered digital application for improving sexual health outcomes, quality of life, and psychological distress in hematopoietic stem cell transplant survivors.",[171,27,77],"Sexual Dysfunction","2026-03-17",{"date":174,"type":37},"2026-03-19",{"date":176,"type":37},"2025-01-27",{"date":178,"type":20},"2030-04-30",{"name":180,"class":127},"Massachusetts General Hospital",3,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":128},"100410355","intestinal-microbiota-in-stem-cell-transplant-transplant-admission-100410355","NCT04623424","Intestinal Microbiota in Stem Cell Transplant Transplant Admission","Intestinal Microbiota Alteration by Antibiotics Used During Stem Cell Transplant Admission","Inclusion Criteria:\n\n* Patients aged 18-80 years\n* patients undergoing allogenic or autologous SCT for malignant hematological conditions or bone marrow failure","80 Years",{"count":191,"type":20},255,"OBSERVATIONAL","In this prospective study, the primary objective will be to investigate the association between the use of antibiotics administered during the admission period of Stem cell transplant (SCT) and the rate of overall change in microbiota composition across adjacent samples in time.",[27],"2026-02-23",{"date":197,"type":37},"2026-02-24",{"date":199,"type":37},"2020-11-03",{"date":201,"type":20},"2028-11-03",{"name":203,"class":127},"Henry Ford Health System",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":21,"phases":213,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":128},"100471633","phase-2-loratadine-for-the-prevention-of-g-csf-related-bone-pain-100471633","NCT05421416","Loratadine for the Prevention of G-CSF-related Bone Pain","Loratadine for the Prevention of Bone Pain Caused by Granulocyte Colony Stimulating Factor (G-CSF) During Stem Cell Mobilization","Inclusion Criteria:\n\n1. A histologically or cytologically documented lymphoma or multiple myeloma\n2. Next line of therapy is autologous stem cell transplant\n3. Adult ≥ 18 years old.\n4. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.\n5. Life expectancy of at least 12 weeks.\n6. The absence of any additional poorly controlled systemic disease that is directly contraindicated or places subject at significant risk, including but not limited to: congestive heart failure, diabetes mellitus, cirrhosis or liver failure, renal failure.\n7. Able to adhere to study protocols and visit schedules\n\nExclusion Criteria:\n\n1. Hypersensitivity or intolerance to antihistamines\n2. Use of antihistamines within two days prior to the study period, excepting the use of single dose antihistamines during chemotherapy or blood transfusion protocols.\n3. Recent use of G-CSF or pegfilgrastim defined as within 12 weeks of study accrual.\n4. New and continued regular use of analgesics within the four days prior to the first dose of G-CSF",{"count":212,"type":20},78,[23],"The research question for the current study is: Is loratadine more effective than placebo in preventing G-CSF-related bone pain during autologous hematopoetic stem cell transplant in patients with lymphoma or multiple myeloma? The hypothesis is that prophylaxis with loratadine will help prevent or reduce the severity of bone pain in this setting.",[27],"2026-02-03",{"date":218,"type":37},"2026-02-05",{"date":220,"type":37},"2024-11-28",{"date":222,"type":20},"2026-12-01",{"name":224,"class":127},"AHS Cancer Control Alberta",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":21,"phases":234,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":251},"100493562","prehabilitation-exercise-training-in-multiple-myeloma-patients-undergoing-autologous-stem-cell-transplantation-100493562","NCT05706766","Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation","Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: The PROTECT Trial","Inclusion Criteria:\n\n* Over 18 years old.\n* All patients will have a diagnosis of multiple myeloma, referral to DFCI transplant team, and assigned to the autologous transplantation waiting list for a first transplant.\n* Planning to receive autologous stem cell transplant after 8 weeks with or without concurrent neoadjuvant treatments at Dana-Farber Cancer Institute.\n* Medical clearance to perform moderate-vigorous intensity aerobic and resistance exercise intervention and fitness testing by their treating physician or a certified clinical exercise physiologist.\n* Speak English.\n* Currently participate in less than or equal to 60 minutes of structured moderate-vigorous intensity exercise\u002Fweek.\n* Willing to travel to Dana-Farber Cancer Institute for necessary data collection.\n* Ability to understand and the willingness to sign a written informed consent document.\n* The effects of exercise on the developing fetus are unknown. For this reason, women of child-bearing potential must agree to undergo a pregnancy test and to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately.\n\nExclusion Criteria:\n\n* History of unstable angina, abnormal resting ECG and\u002For unstable angina or a heart attack in the previous month to allow safe completion of the cardiopulmonary exercise test (CPET) or VO2peak test.\n* Patients with known spinal instability, spinal cord compression or neurological deficits or contraindications that preclude exercise.\n* Those who have had recent (within six weeks) spinal surgery or other intervention surgery for pathological fractures.\n* Those deemed unsuitable to partake by the transplant or study team.\n* Patients at high-risk of impending pathologic fracture of a weight-bearing bone (including spine, hip\u002Ffemur and humerus) as determined by physician.\n* Unable or unwilling to undertake an exercise program on a regular basis.\n* Pre-existing musculoskeletal or cardiorespiratory disease, or metabolic diseases that could exacerbate with exercise, in addition to other conditions deemed unsafe by physician.\n* Patients with other active malignancies requiring active therapy.\n* Participate in more than 60 minutes of structured moderate to vigorous intensity exercise\u002Fweek.\n* Unable to travel to Dana-Farber Cancer Institute for necessary data collection.\n* Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.",{"count":233,"type":20},30,[168],"The goal of this research study is to investigate whether a virtual, home-based, prehabilitation aerobic and resistance exercise (PARE) training program implemented 8 weeks prior to receiving autologous stem cell transplant (ASCT) for multiple myeloma participants will improve muscular strength, physical capacity, patient reported outcomes, and cardiometabolic health outcomes.\n\nThe names of the study interventions involved in this study are:\n\n* Prehabilitative aerobic and resistance exercise (PARE) (virtually supervised 8-week aerobic and resistance exercise program)\n* Waitlist control (8-week normal activity behavior)",[237,27],"Multiple Myeloma",[237,239,240,241],"Autologous Stem Cell Transplant","Aerobic Exercise Program","Resistance Exercise Program","2026-01-20",{"date":244,"type":37},"2026-01-22",{"date":246,"type":37},"2023-06-29",{"date":248,"type":20},"2027-07-31",{"name":250,"class":127},"Dana-Farber Cancer Institute",2,{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":21,"phases":261,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":128},"100620482","early-phase-1-addition-of-venetoclax-to-combined-hematopoietic-stem-cell-and-kidney-transplantation-100620482","NCT07358195","Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation","Addition of Venetoclax to Combined Reduced Intensity Hematopoietic Stem Cell and Kidney Transplantation for Patients With Chronic Kidney Disease and Hematologic Malignancy","Recipient Inclusion Criteria:\n\n* Patient ages 18-70\n* Underlying hematological malignancy which is deemed as being potentially curable with allogeneic bone marrow or PBSC transplantation by the BMT voting team.\n* Hematological malignancies include, but are not limited to: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS. Patient should be in a partial (PR) or complete remission (CR) at the time of the transplant.\n* Existence of an HLA-matched or haploidentical relative who passes standard donor evaluations for bone marrow and kidney donation\n* LVEF \\> 40% as measured by echocardiography or MUGA\n* FEV1, FVC, and DLCO \\> 50% of predicted as measured by standard PFTs\n* Total bilirubin \\\u003C 2.0 (unless diagnosis of Gilbert's or hemolysis is made) and AST, ALT, alkaline phosphatase all \\\u003C 5x institutions upper limit of normal\n* ABO compatibility in the host vs. graft direction\n* Men and women of reproductive potential must agree to use a reliable method of birth control during the treatment, and women should do so for a period of 1 year following the transplant.\n* Participants should be on dialysis or have a CrCl ≤ 35 ml\u002Fmin\n* Life expectancy greater than 6 months\n* Recipient ability to understand and provide informed consent\n\nDonor Inclusion Criteria:\n\n* HLA matched or haploidentical relative as defined by 3\u002F6, 4\u002F6, or 5\u002F6 HLA-matched at HLA -A, -B, or -DRB1 who is 18-70 years of age\n* ECOG performance status 0 or 1\n* Excellent health per conventional pre-donor history (medical and psychosocial evaluation)\n\n  • Acceptable laboratory parameters (hematology in normal or near-normal range; liver function \\\u003C 3 times the upper limit of normal and normal creatinine)\n* Compatible ABO blood group\n* Negative donor lymphocyte cross match\n* No positive testing for active viral infection (Hepatitis B, Hepatitis C, HIV)\n* Donor ability to understand and provide informed consent\n* Meets standard institutional criteria for both bone marrow or peripheral blood stem cell (PBSC) and kidney donation\n\nExclusion Criteria:\n\n* Active serious infection\n* Participation in other investigational drug use at the time of enrollment\n* Positivity for active infection with HIV, HCV, or HBV\n* ABO blood group incompatibility in the host-vs-graft direction","70 Years",{"count":181,"type":20},[262],"EARLY_PHASE1","The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetoclax.",[265,266,27,267,268],"Kidney Failure Chronic","Stem Cell Transplant","Tolerance","Hematologic Cancer","2026-01-13",{"date":244,"type":37},{"date":272,"type":20},"2026-07",{"date":274,"type":20},"2029-12",{"name":180,"class":127},{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":135,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":137,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":21,"phases":285,"briefSummary":286,"conditions":287,"keywords":289,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":128},"100619138","phase-2-novel-first-line-therapies-for-grade-ii-acute-gvhdgraft-versus-host-disease--100619138","NCT07340723","Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )","Novel First-line Therapies for Grade II Acute GVHD: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Diagnosed with hematological diseases.\n2. Have undergone first allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies.\n3. New onset of grade II acute GVHD or intermediate or high risk aGVHD (based on modified GVHD Glucksberg criteria) within 100 days post-transplantation.\n\nExclusion Criteria:\n\n1. Recipients of second allogeneic stem cell transplant.\n2. Acute GVHD induced by donor lymphocyte infusion, interferon.\n3. Received first line aGVHD treatment before enrollment.\n4. Overlap GVHD syndrome.\n5. Pregnant or breast-feeding women.\n6. Pregnant or breast-feeding women.\n7. Serum creatinine \\> 2.0 mg\u002FdL or creatinine clearance \\\u003C 40 mL\u002Fmin measured or calculated by Cockroft-Gault equation.\n8. Uncontrolled infection.\n9. Human immunodeficiency virus infection.\n10. Active hepatitis b virus, hepatitis C virus infection and need antivirus treatment.\n11. Subjects with evidence of relapsed primary disease, or subjects who have been treated for relapse after the allo-HSCT was performed, or graft rejection.\n12. Allergic history to Janus kinase inhibitors.\n13. Severe organ dysfunction unrelated to underlying GVHD, including:\n\n(1)Cholestatic disorders or unresolved veno-occlusive disease of the liver (defined as persistent bilirubin abnormalities not attributable to GVHD and ongoing organ dysfunction).\n\n(2)Clinically significant or uncontrolled cardiac disease including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia that requires therapy.\n\n(3)Clinically significant respiratory disease that requires mechanical ventilation support or 50% oxygen.\n\n14.Received Janus kinase inhibitor therapy after allo-HSCT for any indication. 15.Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.",{"count":284,"type":20},168,[23],"The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for grade II acute GVHD (graft-versus-host disease )",[288,27],"GVHD,Acute",[145,146,147],"2026-01-05",{"date":292,"type":37},"2026-01-14",{"date":294,"type":37},"2025-06-01",{"date":296,"type":20},"2027-06-01",{"name":156,"class":127},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":21,"phases":307,"briefSummary":309,"conditions":310,"keywords":315,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":128},"100414575","phase-1-is-free-treg-haplohct-100414575","NCT04678401","IS-free Treg HaploHCT","A Pilot\u002FPhase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed\u002FRefractory and Ultra-High-risk AML\u002FMDS","Inclusion Criteria:\n\n* Cohort A: Histologically confirmed disease in the prior 4 weeks, despite at least 1 prior line of therapy (e.g., 3+7 chemotherapy, HMA therapy): Rel\u002Fref AML (de novo or secondary) with ≥5% blasts in BM (or extramedullary sites); MDS EB-2 (BM ≥10% blasts, PB 5-19% blasts).\n* Cohort B: Ultra high-risk AML or MDS that meets definition of 'Myeloid Neoplasms with mutated TP53' per 2022 International Consensus Classification (Appendix L) regardless of response\n* Cohort C: Ultra high-risk AML or MDS that meets definition of 'Myeloid Neoplasms with multi-hit or complex karyotype (CK+) mutated TP53' per 2022 International Consensus Classification (Appendix L) with response: AML (de novo or secondary) with \\\u003C5% blasts in BM; MDS with \\\u003C10% blasts in BM or PB.\n* Available haploidentical HLA-matched (-A, -B, -C, -DRB1) related donor aged 18-65 years.\n* Age ≥18 to 65 years for Cohort A and B. Age ≥18 to 75 years for Cohort C. Because no dosing or adverse event data are currently available on the use of IS-free haploHCT in participants \\\u003C18 years of age, children are excluded from this study but will be eligible for future pediatric trials.\n* ECOG performance status ≤2 (Karnofsky ≥60, see Appendix A).\n* Adequate organ and marrow function as defined below:\n\n  * Pulmonary Function: FEV1, FVC and DLCO ≥ 60% of predicted (corrected for hemoglobin)\n  * Cardiac Ejection Fraction ≥ 45%, and no evidence of pulmonary hypertension\n  * Hepatic: Total bilirubin within normal institutional limits (exception permitted in Gilbert's Syndrome after discussion with study PI, on a case-by-case basis); and AST (SGOT)\u002FALT (SGPT) \\\u003C2x institutional upper limit of normal\n  * Renal: Serum Creatinine within normal institutional limits or creatinine clearance \\>50 mL\u002Fmin\u002F1.73 m2 (see Appendix B) for participants with creatinine levels above institutional normal.\n* The effects of IS-free haploHCT on the developing human fetus are unknown. For this reason and because radiation and chemotherapeutic agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and a minimum of 4 months after completion of study.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who have had cytotoxic chemotherapy or radiotherapy within 2 weeks (4 weeks for nitrosoureas or mitomycin C) prior to entering the study. Use of hydroxyurea, HMA, e.g., azacytidine, decitabine) and\u002For FDA-approved novel targeted agents (e.g., venetoclax, FLT-3 inhibitors, IDH 1\u002F2 inhibitors) are permitted up to a day prior to start of HCT conditioning.\n* Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual non-hematologic toxicities \\> Grade 1) with exception of alopecia, unless cleared by study PI.\n* Participants who received Mylotarg or other therapies associated with increased risk of hepatic veno-occlusive disease (VOD) or have known prior or active VOD. All novel therapies will be reviewed with PI.\n* Participants who are receiving any other investigational agents within 21 days (or 5 half-lives) prior to study entry, whichever is longer, unless cleared by the study PI.\n* Participants with extramedullary disease at immune privileged sites (e.g., CNS, testes, eye) are excluded, as these sites are less susceptible to the curative graft vs. leukemia effect of HCT.\n* Myocardial infarction within 2 years prior to enrollment.\n* Venous thromboembolic event (VTE) of DVT\u002F PE within 1 year prior to enrollment, unless approved by study PI. Patients with line-associated DVT within the past year may be enrolled if they have completed anticoagulation therapy.\n* Stroke or transient ischemic attack (TIA) within 1 year prior to enrollment.\n* History of bleeding peptic ulcer disease, erosive gastritis, intestinal perforation or clinically significant gastrointestinal (GI) hemorrhage or hemoptysis within the prior 6 months.\n* Patients with a history of thrombotic microangiopathy (TMA) or hemolytic uremic syndrome\u002Fthrombotic thrombocytopenic purpura (HUS\u002FTTP).\n* History of life-threatening reactions to iron infusions or murine antibody-containing products.\n* Known donor-specific antibodies (DSA) in the recipient of clinical significance (e.g., requiring DSA depletion with plasmapheresis, rituximab) are excluded.\n* Inability to withhold agents that may interact with hepatic cytochrome P450 enzymes involved in cyclophosphamide and\u002For thiotepa metabolism (see Section 5.5) during day -10 through day -5. It is acceptable use alternative non-interacting medications during this period, and then restart prior medications\n* Participants with uncontrolled bacterial, viral or fungal infections (i.e., currently taking medications with progression of clinical symptoms or signs).\n* Recipients of prior allogeneic or autologous hematopoietic cell transplantation, or solid organ transplantation.\n* Prior radiation exposure or other medical condition (e.g., Fanconi syndrome) that precludes use of myeloablative radiation (TMLI).\n* HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with the multiple agents used routinely in myeloablative allogeneic stem cell transplantation. In addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.\n* Participants seropositive for hepatitis B or C infection are ineligible as they are at high risk of lethal treatment-related hepatotoxicity after myeloablative HCT.\n* Participants with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because radiation and conditioning chemotherapy has the potential for teratogenic or abortifacient effects. A negative pregnancy test is required for females of childbearing potential. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with IS-free haploHCT breastfeeding should be discontinued if the mother is treated with IS-free haploHCT.\n* Participants with a history of another non-hematologic malignancy are ineligible except for the following circumstances: Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.","75 Years",{"count":233,"type":20},[308],"PHASE1","This research study is evaluating the safety and efficacy of the IS-free Treg-cell graft-engineered haplo transplant method in people with relapsed\u002Frefractory and Ultra-high risk acute myeloid leukemia (AML) and\u002For myelodysplastic syndromes (MDS) receiving a haploidentical donor allogeneic hematopoietic stem cell transplant (HSCT).\n\nThe names of the study interventions involved in this study are:\n\n* Radiation-Total Myeloid and Lymphoid Irradiation (TMLI)\n* Chemotherapy (Fludarabine, Thiotepa, Cyclophosphamide plus Mesna)\n* Infusion of haplo Treg-enriched donor cells (experimental therapy)\n* Infusion of unmodified haplo donor T cells (includes cancer-fighting T effector cells)\n* Infusion of haplo donor CD34+ Peripheral Blood Stem Cells",[27,311,312,313,314],"Graft Vs Host Disease","Myeloid Leukemia, Acute","Myeloid Leukemia in Relapse (Disorder)","Myelodysplastic Syndromes",[27,311,312,313,314],"2025-10-16",{"date":318,"type":37},"2025-10-20",{"date":320,"type":37},"2021-01-12",{"date":322,"type":20},"2029-08-31",{"name":250,"class":127},{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":16,"minAge":332,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":21,"phases":335,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":350},"100426407","phase-3-multivirus-specific-t-cell-transfer-post-sct-vs-adv-cmv-and-ebv-infections-100426407","NCT04832607","Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections","Treatment of Chemo-refractory Viral Infections After Allogeneic Stem Cell Transplantation With Multispecific T Cells Against CMV, EBV and AdV: A Phase III, Prospective, Multicentre Clinical Trial","TRACE","Inclusion Criteria:\n\n1. Adult or paediatric patients (\\> 2 months of age) after allogeneic stem cell transplantation (SCT) (no time restrictions apply) suffering from new or reactivated CMV or EBV or AdV infection refractory to standard antiviral treatment for two weeks (defined as no decrease or insignificant decrease of less than 1log in viral load over two weeks) as confirmed by quantitative blood PCR analysis.\n2. Original HSCT-donor available with an immune response at least to the virus causing the therapy-refractory (=underlying) infection.\n3. Written informed consent given (patient or legal representative) prior to any study-related procedures.\n\nExclusion Criteria:\n\n1. Patient with acute GvHD \\> grade II or extensive chronic GvHD at the time of IMP transfer\n2. Patient receiving steroids (\\>1 mg\u002Fkg BW Prednisone equivalent) at Screening.\n3. Therapeutic donor lymphocyte infusion (DLI) from 4 weeks prior to IMP infusion until 8 weeks post IMP infusion. Prescheduled prophylactic DLI ≤3x105 T cells\u002Fkg BW in case of T-cell depleted HSCT is not considered an exclusion criterion.\n4. Patient with organ dysfunction or failure as determined by Karnofsky (patients \\>16 years) or Lansky (patients ≤16 years) score ≤30%\n5. Concomitant enrolment in another clinical trial interfering with the endpoints of this study\n6. Any medical condition which could compromise participation in the study according to the investigator's assessment\n7. Progression of underlying disease (disease that has led to the indication of HSCT, e.g. leukaemia) that will limit the life expectance below the duration of the study\n8. Second line or experimental antiviral treatment other than Ganciclovir\u002FValganciclovir, Foscarnet, Cidofovir and Rituximab until 8 weeks after IMP Infusion or prophylactic Treatment other than Aciclovir or Letermovir throughout the study except approved by sponsor\n9. Known HIV infection. In case patients do not have a negative HIV test performed within 6 months before enrolment in the study, HIV negativity has to be confirmed by a negative laboratory test.\n10. Female patient who is pregnant or breast-feeding. Female patient of child-bearing potential (i.e. post menarche and not surgically sterilized) or male patient of reproductive potential not willing to use an effective method of birth control from Screening until the last follow-up visit (FU6, Visit 8).\n\n    Note: Women of childbearing potential must have a negative serum pregnancy test at study entry ≤7 days before IMP administration on Day 0. Acceptable birth control methods are hormonal oral contraceptive ('pill'), contraceptive injection or patch, intrauterine pessar or the combination of two barrier methods. The combination of female and male condomes is NOT acceptable. If the male partner is sterilized, no further contraceptive is required. Women of post-menopausal status (no menses for 12 months without an alternative medical cause) are also not required to use contraceptives during the study.\n11. Known hypersensitivity to iron dextran\n12. Patients unwilling or unable to comply with the protocol or unable to give informed consent.","2 Months",{"count":334,"type":20},149,[56],"Haematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality. Adoptive transfer of virus-specific T cells is an attractive approach to restore protective T-cell immunity in patients with refractory viral infections after allogeneic HSCT. The aim of this Phase III trial is to confirm efficacy of this treatment in children and adults.",[338,339,340,27],"AdV Infection","EBV Infection","CMV Infection","2025-07-15",{"date":343,"type":37},"2025-07-18",{"date":345,"type":37},"2019-08-27",{"date":347,"type":20},"2028-09",{"name":349,"class":127},"Tobias Feuchtinger",33,{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":16,"minAge":358,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":21,"phases":362,"briefSummary":363,"conditions":364,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":251},"100552094","developing-restful-environments-and-management-strategies-for-pediatric-stem-cell-transplant-patients-100552094","NCT06468618","Developing Restful Environments and Management Strategies for Pediatric Stem Cell Transplant Patients","DREAMS","Inclusion Criteria:\n\n* Patient aged 9-17 years.\n* Patient scheduled to receive a stem cell transplant at Boston Children's Hospital.\n* English speaking child and primary caregiver (parent\u002Fguardian).\n\nExclusion Criteria:\n\n-Primary team declines permission to approach.","9 Years","17 Years",{"count":361,"type":20},10,[168],"Pediatric patients undergoing stem cell transplant (SCT) are hospitalized for extended periods and are at high risk for sleep disturbances. In order to begin to address the environmental issues that SCT recipients face during inpatient hospitalizations, investigators will conduct a single arm pilot study of a program entitled 'Developing Restful Environments and Management Strategies' (DREAMS). The program will provide children receiving SCT and families with information and a kit that includes tools which may support sleep and circadian health during an inpatient hospitalization.",[27,365],"Sleep Disturbance","2025-07-14",{"date":341,"type":37},{"date":369,"type":37},"2024-08-06",{"date":371,"type":20},"2026-08",{"name":250,"class":127},{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":21,"phases":383,"briefSummary":384,"conditions":385,"keywords":387,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":394,"leadSponsor":396,"locationsCount":4},"100593717","nutritional-support-with-tgf-2-food-for-special-medical-purposes-tgf-2-fsmp-in-adult-allogeneic-hematopoietic-stem-cell-transplantation-allo-hsct-for-the-prevention-of-malnutrition-a-prospective-randomized-multicenter-study-100593717","NCT07010068","Nutritional Support With TGF-β2 Food for Special Medical Purposes (TGF-β2 FSMP) in Adult Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) for the Prevention of Malnutrition: a Prospective, Randomized, Multicenter Study","Nutritional Support With TGF-β2 Food for Special Medical Purposes (TGF-β2 FSMP) in Adult Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) for the Prevention of Malnutrition: a Prospective, Randomized, Multicenter Study - (TGF-NUTRIALLO Study)","TGF-Nutri","Inclusion Criteria:\n\n* Intact intestinal tract\n* Life expectancy more than 12 weeks\n* Allogeneic stem cell transplantation\n* Signed informed consent\n\nExclusion Criteria:\n\n* Active hematological disease at the beginning of conditioning\n* Personal history of inflammatory bowel diseases\n* Personal history of bowel resection\n* Personal history of gastric bypass procedures\n* Enrolment in a competitive prospective study (malnutrition or GVHD as primary outcome)\n* Subjects with known hypersensitivity to milk proteins or components of Modulen-IBD",{"count":382,"type":20},214,[168],"prospective, randomized, multicenter study to confirm the potential benefits of TGF-β2 enriched FSMP. The primary objective is to evaluate the superiority of supplementing with TGF-β2 FSMP (experimental arm) compared to best supportive treatment (BST) in preventing malnutrition in patients submitted to allo-SCT. The secondary endpoints include the assessment of reduction of incidence of severe acute GVHD at day +100.",[386,27],"Malnutrition (Calorie)",[266,388,389],"malnutrution","gvhd","2025-06-04",{"date":392,"type":37},"2025-06-08",{"date":294,"type":20},{"date":395,"type":20},"2028-06",{"name":397,"class":127},"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia",{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":16,"minAge":137,"maxAge":405,"enrollmentInfo":406,"targetDuration":4,"studyType":21,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":417,"locationsCount":128},"100560078","phase-2-atg-individualized-dosing-model-in-urd-pbsct-100560078","NCT06572462","ATG Individualized Dosing Model in URD-PBSCT.","Application of Thymoglobulin (ATG) Individualized Dosing Model in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.","Inclusion Criteria:\n\n1. Patients with malignant hematological tumors who have indications for allogeneic hematopoietic stem cell transplantation.\n2. HLA-matched unrelated donor\n3. Patient age ≥14 years old and ≤65 years old\n4. ALT and AST ≤ 2.5 times the upper limit of normal values, bilirubin ≤ 2 times the upper limit of normal values\n5. Creatinine ≤ high limit of normal value\n6. No uncontrollable infection or serious mental illness\n7. Physical strength score is 0-2 (ECOG)\n8. Sign the informed consent form\n\nExclusion Criteria:\n\n1. Unrelated donor who is not HLA matched\n2. No indication for allogeneic hematopoietic stem cell transplantation\n3. Patient age \\\u003C14 years old or \\>65 years old\n4. The donor or recipient are pregnant\n5. Suffering from mental illness or other conditions and being unable to proceed as planned","65 Years",{"count":233,"type":20},[23],"Anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation to prevent severe graft-versus-host disease (GVHD) and graft failure. However, overexposure to ATG may increase cytomegalovirus (CMV), Epstein-Barr virus (EBV) reactivation, non-relapse mortality, and disease recurrence. A targeted dosing strategy was established based on ATG concentration monitoring and conducted a phase 2 trial to evaluate the safety and efficacy of the dosing strategy in adult unmanipulated haplo-PBSCT, a encouraging result was attained. In this trial, The ATG-targeted dosing strategy was extended to adult unrelated donor allogeneic hematopoietic stem cell transplantation, ATG was administered for 4 days (-5 days to -2 days) during conditioning. The ATG doses on-3 days and- 2days were adjusted by our dosing strategy to achieve the optimal ATG exposure. The primary endpoint was CMV reactivation on +180 days.",[410,411,27],"Cytomegalovirus Infections","Infection Reactivation",{"date":413,"type":37},"2024-12-03",{"date":415,"type":37},"2020-12-31",{"date":152,"type":20},{"name":418,"class":127},"Chinese PLA General Hospital",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":16,"minAge":137,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":21,"phases":427,"briefSummary":428,"conditions":429,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":128},"100555473","modified-second-haplo-transplantation-for-graft-failure-100555473","NCT06512545","Modified Second Haplo-transplantation for Graft Failure","Second Haploidentical Transplantation with Modified Regimen for Graft Failure After the First Allogeneic Stem Cell Transplantation","Inclusion Criteria:\n\n* 1.Primary disease: hematological malignancies(AML, CML, MDS, lymphoma, etc.); 2.Graft failure after first allogeneic stem cell transplantation; 3.Time from the first transplantation to the second transplantation is less than 180 days; 4. Age≥14 years.\n\nExclusion Criteria:\n\n* 1\\. Active infections; 2. Active GVHD; 3. Organ dysfunction: hepatic injury (Tbil≥2ULN), renal injury (Cr≥1.5ULN), heart injury (EF%\\\u003C50% or symptomatic heart failure); 4. Eastern Cooperative Oncology Group (ECOG) score\\>2; 5. Expected life time\\\u003C30 days; 5. Patients could not cooperate; 6. Other situations that are considered inappropriate for enrollment by the investigators,",{"count":105,"type":20},[168],"Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage. We previously reported encouraging results with a novel Flu\u002FCy regimen. However, there are still around 20% patients developed delayed platelet recovery. We designed a modified regimen to further improve the hematopoietic reconstitution after second transplantation. This prospective, single-arm study aims to investigate the safety and efficacy of this modified regimen.",[430,27],"Graft Failure","2024-11-26",{"date":433,"type":37},"2024-11-29",{"date":435,"type":37},"2024-07-01",{"date":437,"type":20},"2026-06-30",{"name":439,"class":127},"Peking University People's Hospital",{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":16,"minAge":137,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":21,"phases":449,"briefSummary":450,"conditions":451,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":456,"leadSponsor":458,"locationsCount":128},"100555471","second-haplo-transplantation-for-graft-failure-100555471","NCT06512519","Second Haplo-transplantation for Graft Failure","A Multicenter Prospective Study of Second Haploidentical Transplantation for Graft Failure After the First Haploidentical Transplantation","Inclusion Criteria:\n\n* 1\\. Primary disease: hematological malignancies (AML, CML, MDS, lymphoma, etc.); 2. Graft failure after the first haploidentical stem cell transplantation; 3. Time from the first transplantation to the second transplantation is less than 180 days; 4. Age≥14 years.\n\nExclusion Criteria:\n\n* 1\\. Active infections; 2. Active GVHD; 3. Organ dysfunction: hepatic injury (Tbil≥2ULN), renal injury (Cr≥1.5ULN), heart injury (EF%\\\u003C50% or symptomatic heart failure); 4. Eastern Cooperative Oncology Group (ECOG) score\\>2; 5. Expected life time\\\u003C30 days; 5. Patients could not cooperate; 6. Other situations that are considered inappropriate for enrollment by the investigators,",{"count":448,"type":20},34,[168],"Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage. There are no recommended regimens for second transplantations for graft failure, especially in the haploidentical transplant setting. We recently reported encouraging outcomes using a novel method (haploidentical transplantation from a different donor after conditioning with fludarabine and cyclophosphamide). However, the study was performed in single-center and with very small sample size. Therefore, it should be further validated via multicenter study. In this multi-center study, we aim to further evaluate the safety and efficacy of this protocol.",[430,27],"2024-11-05",{"date":454,"type":37},"2024-11-07",{"date":435,"type":37},{"date":457,"type":20},"2027-06",{"name":439,"class":127},{"id":460,"slug":461,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":405,"enrollmentInfo":467,"targetDuration":4,"studyType":21,"phases":469,"briefSummary":470,"conditions":471,"keywords":473,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":484},"100531655","phase-2-efficacy-and-safety-of-avatrombopag-in-the-treatment-of-thrombocytopenia-after-haplo-hsct-100531655","NCT06202625","Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT","Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haploidentical Hematopoietic Stem Cell Transplantation: Prospective, Multi-center, Double-blinded, Randomized Placebo-controlled Study","Haplo-HSCT","Inclusion Criteria:\n\n1. Male or female, aged between 18-65 years;\n2. PLT\\\u003C20×10\\^9\u002FL or transfusion dependent on +D7 after haplo-HSCT;\n3. Agree to receive the treatment of avatrombopag after Haplo-HSCT and sign the informed consent form.\n\nExclusion Criteria:\n\n1. With active infection;\n2. ALT or AST\\>3ULN, or total Bil\\>2ULN\n3. Ccr\\\u003C50 mL\u002Fmin;\n4. With the history of arteriovenous thrombosis;\n5. With history of cardiovascular disease (such as NYHA Class III\u002FIV congestive heart failure, arrhythmia that increases the risk of thromboembolic events \\[such as atrial fibrillation\\] and angina), and subjects who have undergone coronary stent implantation, angioplasty, or coronary artery bypass grafting;\n6. With treatment of drugs to promote platelet production two weekes before enrollment, including but not limited to rhTPO and TPO-RA;\n7. HBsAg or anti-HCV or anti-HIV positive;\n8. Known to be allergic to avatrombopag and any of its excipients;\n9. With secondary or multiple HSCT;\n10. Females who were pregnant or breastfeeding or who had fertile ability but refuse to take effective contraceptive measures during and one month after this trial;\n11. With any other clinical trial of investigational product or device within 30 days prior to the baseline visit, except for observational study;\n12. Deemed unsuitable for enrollment by the investigator for any history of or concomitant medical condition.\n13. Concomitant medication:The rhIL-11, rhTPO or TPO-RA(such as eltrombopag, hetrombopag and romiplostim) and desitabine, etc. were not allowed for use during this trial.",{"count":468,"type":20},142,[23,56],"In this study, investigators aim to evaluate the efficacy of avatrombopag in thrombocytopenic patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) through a prospective, multi-center, double-blinded, randomized placebo-controlled clinical trial.",[472,27],"Thrombocytopenia",[472,474,475],"hematopoietic stem cell transplantation","haploidentical","2024-09-29",{"date":478,"type":37},"2024-10-01",{"date":480,"type":37},"2024-05-13",{"date":482,"type":20},"2025-10-30",{"name":439,"class":127},14,{"id":486,"slug":487,"hasResults":11,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":491,"eligibilityCriteria":492,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":21,"phases":495,"briefSummary":496,"conditions":497,"keywords":502,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":128},"100453908","early-integration-of-palliative-and-supportive-care-in-cellular-therapy-100453908","NCT05190653","Early Integration of Palliative and Supportive Care in Cellular Therapy","Early Integration of Palliative and Supportive Care for Patients and Family Caregivers Undergoing Hematopoietic Stem Cell Transplantation or Chimeric Antigen Receptor T-Cell Therapy: A Prospective Pragmatic Randomized Clinical Trial","PALS_CT","Inclusion Criteria - Patients\n\n* Clinical diagnosis of hematologic malignancy with scheduled hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy\n* Ability to speak, read, and understand English or, be able to complete questionnaires with minimal assistance required from an interpreter\n\nInclusion Criteria - Family Caregivers\n\n* Family caregivers of patients with a clinical diagnosis of hematologic malignancy with scheduled hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T-cell therapy\n* A spouse, relative, or friend, identified by the patient, who either lives with the patient or has in-person contact with the patient at least twice per week. Only one family CG per patient will be asked to participate.\n* Ability to speak, read, and understand English or willing to complete questionnaires with minimal assistance required from an interpreter\n\nExclusion Criteria - Patients\n\n* Patients undergoing HSCT for a non-malignant hematologic condition\n* Inability to provide informed consent\n\nExclusion Criterion - Family Caregivers\n\n\\* Inability to provide informed consent",{"count":494,"type":20},152,[168],"Research has shown that early palliative care in cancer care is associated with improved symptom management, better prognostic understanding, improved quality of life for patients and family caregivers, and even improved survival. Yet, in spite of the proven benefits of integration of palliative care in oncology, it has been well established that patients with hematologic malignancies and those undergoing cellular therapy (hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor (CAR) T-cell therapy) do not routinely receive palliative care. Most of the published research on the early integration of palliative care in oncology describes studies that have involved patients with solid tumours. To date, only one randomized trial examining the impact of integrated palliative care among patients undergoing HSCT has been published and there have been no studies examining the impact of integrated palliative care for patients undergoing CAR T-cell therapy. The American Society of Clinical Oncology recommends early palliative care for patients with advanced cancers or for those with high symptom burden. Patients with blood cancers experience high symptom burden and in the last 30 days of life, compared to patients with solid tumours, patients with blood cancers are more likely to die in hospital, have more intensive care unit admissions, have prolonged hospitalizations (\\>14 days), and pass away in an acute care facility. There is an urgent need to proactively address suffering throughout cellular therapy trajectories, even before treatment starts, so that patients and caregivers are not inevitably waiting for symptoms to arise before they can be addressed and to optimize quality of life for patients undergoing transplant as well as their family caregivers.\n\nPALS\\_CT will compare early palliative care to standard care for patients and their family caregivers undergoing HSCT or CAR T-cell therapy for blood cancers.",[498,499,237,500,27,501],"Leukemia","Lymphoma","Blood Cancer","Chimeric Antigen Receptor T-cell Therapy",[503,504,505,506,507],"palliative care","supportive care","quality of life","symptom burden","hematologic malignancies","2024-07-30",{"date":510,"type":37},"2024-07-31",{"date":512,"type":37},"2022-04-08",{"date":514,"type":20},"2025-12",{"name":516,"class":127},"Alberta Health Services, Calgary",{"id":518,"slug":519,"hasResults":11,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":11,"sex":16,"minAge":524,"maxAge":405,"enrollmentInfo":525,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":527,"conditions":528,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":4},"100545787","study-on-the-serum-metabolic-markers-and-early-complications-after-allo-hsct-cohort-study-100545787","NCT06386445","Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study","Study on the Serum Metabolic Markers and Early Complications After Allogeneic Hematopoietic Stem Cell Transplantation in Hemaotological Diseases： Cohort Study","Inclusion Criteria:\n\n* Age ≤ 65 years old;\n\nGender unlimited;\n\nNormal heart and kidney function before transplantation;\n\nPatients with indications for allogeneic hematopoietic stem cell transplantation.\n\nExclusion Criteria:\n\n* CREA or BUN higher than the normal upper limit value before transplantation;\n\nIndividuals with a history of arrhythmia, heart failure, or PCI stent implantation prior to transplantation;\n\nPatients with mental illness;\n\nThose who are unwilling to sign informed consent.","0 Years",{"count":526,"type":20},500,"This study aims to establish a cohort of 500 patients with hematological disease who undergoing allogeneic hematopoietic stem cell transplantation in the northwest region. All patients will be followed up at the outpatient clinic once a week after transplantation until 100 days after transplantation to observe the presence of acute graft versus host disease, acute kidney damage, and major cardiovascular adverse events. Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks，4 weeks，8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.The primary objective is to explore the serum metabolic markers of acute graft versus host disease，acute kidney injury, and major adverse cardiac events within 100 days after transplantation，the secondary objective is to observe the high-risk factors for early complications.",[27,529,530,531],"Acute Graft Versus Host Disease","Acute Kidney Injury","Major Adverse Cardiac Events","2024-04-23",{"date":534,"type":37},"2024-04-26",{"date":536,"type":20},"2024-05-01",{"date":538,"type":20},"2026-12-31",{"name":540,"class":127},"First Affiliated Hospital Xi'an Jiaotong University",{"id":542,"slug":543,"hasResults":11,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":548,"sex":16,"minAge":17,"maxAge":405,"enrollmentInfo":549,"targetDuration":4,"studyType":21,"phases":551,"briefSummary":552,"conditions":553,"keywords":555,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":566,"locationsCount":128},"100448941","phase-2-aza-combined-with-nac-for-pit-after-hsct-100448941","NCT05126004","AZA Combined With NAC for PIT After HSCT","Azacitidine (AZA) Combined With N-Acetyl-L-cysteine (NAC) for Prolonged Isolated Thrombocytopenia (PIT) After Hematopoietic Stem Cell Transplantation (HSCT)","Inclusion Criteria:\n\n* Platelet count ≤ 30 × 10\\^9\u002FL persistently at day 60 post-HSCT or later;\n* Neutrophil and hemoglobin were well recovered;\n* Full donor chimerism was achieved;\n\nExclusion Criteria:\n\n* Patients with malignancy relapse;\n* Active infections;\n* Grade Ⅲ-Ⅳ acute graft-versus-host disease or severe chronic graft-versus-host disease according to National Institute of Health criteria;\n* Severe organ damage;\n* Thrombosis requiring treatment;",true,{"count":550,"type":20},100,[23],"Prolonged isolated thrombocytopenia (PIT) that is refractory to conventional treatments has remained a critical complication after allogeneic hematopoietic cell transplantation since decades years ago. Recombinant human thrombopoietin (rhTPO) is the main therapy in clinical practice, but remains low efficiency for PIT. Demethylating drugs have shown thier potential in high-risk myelodysplastic syndromes (MDS) and acte myeloid leukemia (AML). In addition, decitabine has demonstrated its efficacy of over 70% for response rate in treatment for PIT in early clinical trials with elusive mechanism. Preliminary experiments revealed that PIT was associated with abnormality of oxidation microenvironment, and N-Acetyl-L-cysteine (NAC) was the most commonly used antioxidant. Therefore, the investigators have been wondering whether Azacitidine in combination with NAC could improve PIT post HSCT and explore the possible mechanism of it.",[554,27],"Thrombocytopenia, Isolated",[556,557,558,559],"Azacitidine","N-Acetyl-L-cysteine","Prolonged Isolated Thrombocytopenia","Hematopoietic Stem Cell Transplantation","2021-11-08",{"date":562,"type":37},"2021-11-18",{"date":564,"type":20},"2021-12-01",{"date":437,"type":20},{"name":567,"class":127},"The First Affiliated Hospital of Soochow University",{"id":569,"slug":570,"hasResults":11,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":574,"eligibilityCriteria":575,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":576,"targetDuration":4,"studyType":21,"phases":578,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":4},"100446003","allolife---life-after-transplantation-100446003","NCT05087784","AlloLife - Life After Transplantation","AlloLife - Life After Allogeneic Hematopoietic Stem Cell Transplantation","AlloLife","Inclusion Criteria:\n\n* Age \\> 18\n* Patients with performed allogeneic stem cell transplantation any type of donor, stem cell source, GVHD prophylaxis or conditioning regimen and at least at day +20 after HCT.\n* Hematologic Remission after HCT at study entrance, MRD positive patients are allowed to enter the study\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-3\n* Signature of informed and written consent by the subject or by the subject's legally acceptable representative for patients under guardianship or trusteeship to participate in the study\n* Access to an internet connected device (smartphone\u002Ftablet\u002Fcomputer)\n* Able to understand and communicate in the respective language\n* Consent to use a wearable device through the time of the study\n* Consent to use a chatbot application for both healthcare data exchange and psychologic intervention\n\nExclusion Criteria:\n\n* Missing consent to use a wearable device and contribute personal data collected at the point of life to the study\n* ECOG performance status of 4\n* Relapse of the disease at study inclusion\n* Uncontrolled systemic infection\n* Diagnosis of a secondary malignancy requiring systemic therapy\n* Reported ongoing severe depression or potential suicidal ideation\n* Vulnerable patients such as: minor, persons deprived of liberty, persons in Intensive Care Unit unable to provided informed consent prior to the intervention\n* Other ongoing interventional protocol that might interfere with the current study primary endpoint",{"count":577,"type":20},192,[168],"Survivors of allo HCT can experience long-term survival, which is however limited by a number of late effects. These will be addressed in AlloLife to improve quality of life (QoL) and survival.",[581,27],"Survivorship",{"date":583,"type":37},"2021-11-16",{"date":585,"type":20},"2024-03",{"date":587,"type":20},"2026-06",{"name":589,"class":127},"University Hospital, Essen",{"id":591,"slug":592,"hasResults":11,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":597,"enrollmentInfo":598,"targetDuration":4,"studyType":21,"phases":600,"briefSummary":601,"conditions":602,"keywords":605,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":128},"100346652","phase-2-decitabine-plus-mbucy-for-high-risk-acute-leukemia-with-mrd-pre-hsct-100346652","NCT03793517","Decitabine Plus mBU\u002FCY for High Risk Acute Leukemia With MRD Pre-HSCT","Decitabine Plus mBU\u002FCY for High Risk Acute Leukemia With Minimal Residual Disease Pre-HSCT","Inclusion Criteria:\n\n* acute leukemia patients with MLL-r,TLS-ERG,or SIL-TAL1,whose minimal residual disease were detectable pre-HSCT\n\nExclusion Criteria:\n\n* pregnancy women\n* uncontrolled severe infection","55 Years",{"count":599,"type":20},55,[23,56],"Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly causes of transplant failure. We reported previously that patients with high-risk molecular biomarkers who still have detectable minimal residual disease(MRD) pre-HSCT were at very high risk of relapse, with cumulative relapse rate of 50-80%. Decitabine has been demonstrated efficacy in the treatment of patients with recurrent or refractory leukemia and myelodysplastiv syndrome. It was reported that the combination of decitabine, with busufan and cyclophosphamide as a preparative regimen for allo-HSCT using HLA-matching donors was safe and effective. In this prospective, single-arm clinical trial, we aimed to examine the efficacy of combining decitabine with modified busulfan and cyclophosphamide (mBU\u002FCY) as a preparative regimen for allo-HSCT in patients with very high-risk AL and detectable MRD pre-HSCT.",[27,603,604],"Leukemia, Myeloid, Acute","Leukemia Relapse",[606,474,607,608,609],"high risk acute myeloid leukemia","leukemia relapse","preparation regimen","decitabine","2020-03-09",{"date":612,"type":37},"2020-03-10",{"date":614,"type":37},"2018-09-01",{"date":616,"type":20},"2026-10",{"name":439,"class":127}]